Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Narsoplimab (OMS721) in IgA Nephropathy
NCT03608033Phase 3Terminated
- Sponsor
- Omeros Corporation
- Start
- Apr 2018
- Primary completion
- Jan 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing OMS721 with Placebo (2 arms). Primary endpoint: 24-hour Urine Protein Excretion at 36 weeks. Started Apr 2018; status: terminated.
02
Drugs
narsoplimab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT03608033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608033.